LRRK2 and Parkinson disease: Rodent models with pathogenic PD-linked LRRK2 mutations display increased accumulation of insoluble α-synuclein inclusions and greater α-synuclein-induced neurodegeneration, which can be reversed by LRRK2 kinase inhibition [18, 71, 89].